Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome

Cancer Science

Volumn 108, Issue 12, 2017, Pages 2445-2453

  Ueda, Yasunori ^a   Ogura, Michinori ^b,i   Miyakoshi, Shigesaburo ^c   Suzuki, Takahiro ^d,j   Heike, Yuji ^e,k   Tagashira, Shuzo ^f   Tsuchiya, Satoru ^f   Ohyashiki, Kazuma ^g   Miyazaki, Yasushi ^h  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f Sumitomo Dainippon Pharma   (Japan)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

^h NAGASAKI UNIVERSITY   (Japan)

ⁱ Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^j KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

more..

Author keywords

Acute myeloid leukemia; azacitidine refractory patients; myelodysplastic syndrome; synthetic peptide vaccine; Wilms tumor 1 protein

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CREATINE KINASE; GALINPEPIMUT S; HEMOGLOBIN; HLA A24 ANTIGEN; UNCLASSIFIED DRUG; WT 4869; CANCER VACCINE; SUBUNIT VACCINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLADDER CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTUSION; CREATINE KINASE BLOOD LEVEL; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; INJECTION SITE REACTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOPENIA; LUNG INFECTION; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SEPSIS; SIDE EFFECT; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; DOSE RESPONSE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; VACCINES, SUBUNIT;

EID: 85037031478     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13409     Document Type: Article

References (28)

1. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–88.
2. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–65.
3. Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood 2014; 124: 2793–803.
4. Greenberg PL, Stone RM, Bejar R et al. Myelodysplastic syndromes, version 2.2015. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2015; 13: 261–72.
5. Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015; 90: 831–41.
6. Prébet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322–7.
7. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: Therapeutic potential of WT1 targeted therapies. Leukemia 2003; 17: 1301–12.
8. Qi XW, Zhang F, Wu H et al. Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep 2015; 5: 8924.
9. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323–37.
10. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286–93.
11. Azuma T, Makita M, Ninomiya K et al. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 2002; 116: 601–3.
12. Tsuboi A, Oka Y, Udaka K et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51: 614–20.
13. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Nat Acad Sci USA 2004; 101: 13885–90.
14. Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008; 20: 211–20.
15. Oka Y, Tsuboi A, Murakami M et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003; 78: 56–61.
16. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937–51.
17. Cheson BD, Greenberg PL, Bennett JM et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–25.
18. Iiyama T, Udaka K, Takeda S et al. WT1 (Wilms’ tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007; 51: 519–30.
19. Tsuboi A, Oka Y, Osaki T et al. WT1 peptide-based immunotherapy for patients with lung cancer: Report of two cases. Microbiol Immunol 2004; 48: 175–84.
20. Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002; 99: 3272–9.
21. Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 2015; 6: 36.
22. Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol 2016; 17(4): 496–508.
23. Komrokji RS, Padron E, Yu D et al. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol 2014; 89: 809–12.
24. Duong VH, Jaglal MV, Zhang L et al. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res 2013; 37: 300–4.
25. Brayer J, Lancet JE, Powers J et al. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol 2015; 90: 602–7.
26. + T cells in myeloid malignancies. Haematologica 2011; 96: 432–40.
27. Harel S, Cherait A, Berthon C et al. Outcome of patients with high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML) treated with decitabine after azacitidine failure. Leuk Res 2015; 39: 501–4.
28. Duong VH, Lin K, Reljic T et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk 2013; 13: 711–5.